Effective alpha-particle-mediated radioimmunotherapy of murine leukemia.

Abstract

The specificity, toxicity, and efficacy of alpha-particle-mediated radioimmunotherapy of murine erythroleukemia was assessed by use of tumor-specific monoclonal antibody 103A labeled with 212Bi. Forty % of the injected dose/g tissue targeted to neoplastic spleens within 1 h after i.v. injection. When 212Bi-103A was injected on day 13 of disease, a dose-dependent response was achieved, as measured by a reduction in splenomegaly and absence of liver metastasis. Mice treated with 212Bi-103A on day 8 of disease showed no histological evidence of erythroleukemia on day 22 and survived significantly longer (median, 118 days) than mice treated with 212Bi-control IgG (78 days) or untreated mice (63 days), indicating successful specific radioimmunotherapy.

• Authors: R B Huneke, C G Pippin, R A Squire, M W Brechbiel, O A Gansow, M Strand
• Journal: Cancer research (Cancer Res) Vol. 52 Issue 20 Pg. 5818-20 (Oct 15 1992) ISSN: 0008-5472 [Print] United States
• PMID: 1394209 (Publication Type: Comparative Study, Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antibodies, Monoclonal
• Immunoglobulin G
• Radioisotopes
• Bismuth

Topics

• Alpha Particles (therapeutic use)
• Animals
• Antibodies, Monoclonal (therapeutic use)
• Bismuth (pharmacokinetics, therapeutic use)
• Cattle
• Immunoglobulin G (therapeutic use)
• Mice
• Radioimmunotherapy
• Radioisotopes (pharmacokinetics, therapeutic use)
• Rauscher Virus